Literature DB >> 6199592

The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro--inhibition of 12-HPETE biosynthesis.

H Darius, B Ahland, W Rücker, W Klaus, B A Peskar, K Schrör.   

Abstract

We studied the action of the biologically active metabolite of molsidomine, N-morpholino-N-nitrosoamino-acetonitrile (SIN), on eicosanoid formation and functional behavior of bovine coronary arteries and human platelets in vitro. Glyceryltrinitrate (GTN) and prostaglandin (PG) I2 were used as reference compounds. SIN dose-dependently inhibited the thrombin-, collagen-, and primary ADP-induced platelet aggregation. The IC50 was in the range of 0.1-0.8 mumol/L. At these concentrations SIN also inhibited thromboxane formation, but did not influence the PGI2 biosynthesis of coronary vessels. Molsidomine itself was inactive. GTN stimulated vascular PGI2 formation, but did not modify the platelet aggregation at comparable concentrations. A particularly interesting finding was the dose-dependent and apparently complete inhibition of formation of the hydroperoxide of 12L-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HPETE) in human platelets by SIN. The IC50 amounted to 1.7 +/- 0.4 mumol/L and was in the same range as with 5,8,11,14-eicosatetraynoic acid (2.0 +/- 0.3 mumol/L). Although the results may not suggest a common mechanism of the antiaggregatory action of GTN and SIN, they provide no evidence of a similar or dissimilar mechanism of action in vascular smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199592

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.

Authors:  H Darius; V Hossmann; K Schrör
Journal:  Klin Wochenschr       Date:  1986-06-16

2.  [Inhibition of platelet aggregation and thromboxane formation by the calcium antagonist nisoldipine following a single oral dose of 10 mg. A double-blind study in healthy probands].

Authors:  K Schrör; G Latta; H Darius; W Klaus; R Ziegler
Journal:  Klin Wochenschr       Date:  1985-01-02

Review 3.  Endogenous and exogenous nitrates and their role in myocardial ischaemia.

Authors:  T F Lüscher
Journal:  Br J Clin Pharmacol       Date:  1992       Impact factor: 4.335

4.  Comparison of the effects of molsidomine, nitroglycerin and isosorbide dinitrate on experimentally induced coronary artery thrombosis in the dog.

Authors:  P A Martorana; B Kettenbach; H Göbel; R E Nitz
Journal:  Basic Res Cardiol       Date:  1984 Sep-Oct       Impact factor: 17.165

5.  The effects of the nitric oxide donors molsidomine and SIN-I on human polymorphonuclear leucocyte function in vitro and ex vivo.

Authors:  H Darius; L Grodzinska; J Meyer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Molsidomine on cardiovascular leukotriene D4 actions.

Authors:  V B Fiedler; T S Abram
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

7.  Molsidomine prevents post-ischaemic ventricular fibrillation in dogs.

Authors:  J P Cano; J C Guillen; R Jouve; F Langlet; P E Puddu; P H Rolland; A Serradimigni
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

8.  Cytoprotective Effects of Dinitrosyl Iron Complexes on Viability of Human Fibroblasts and Cardiomyocytes.

Authors:  Natalia Pavlovna Akentieva; Natalia Alekseevna Sanina; Artur Rasimovich Gizatullin; Natalia Ivanovna Shkondina; Tatyana Romanovna Prikhodchenko; Stanislav Ivanovich Shram; Nikolai Zhelev; Sergei Michailovich Aldoshin
Journal:  Front Pharmacol       Date:  2019-11-11       Impact factor: 5.810

9.  Cyclooxygenase-2 Glycosylation Is Affected by Peroxynitrite in Endothelial Cells: Impact on Enzyme Activity and Degradation.

Authors:  Sonia Eligini; Susanna Colli; Aida Habib; Giancarlo Aldini; Alessandra Altomare; Cristina Banfi
Journal:  Antioxidants (Basel)       Date:  2021-03-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.